Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

The hotly anticipated approval of orforglipron for obesity came through in record time, with the company planning to start shipping it on April 6.

Alto Neuroscience’s ALTO-101 has missed significance in a proof-of-concept study in schizophrenia patients, prompting the firm to stand even more squarely behind its lead depression asset, ALTO-207.

India has cut import duty on 40 petrochemical products to nil and reduced rates on domestic sales from SEZs as input, freight costs rise due to the Iran war. The Essential Commodities Act might also be invoked, but how much of an impact will it have on pharma?

Tanabe plans US NDA for first oral option for rare skin disorders EPP and XLP, as it looks to fill gap from Radicava divestment and overcome regulatory challenges for some other late-stage candidates.

Centessa’s lead drug candidates are being tested in narcolepsy and hypersomnia, but the orexin pathway has potential in an array of CNS disorders.